Geriatria e Malattie Metaboliche dell'Osso, Dipartimento di Scienze Mediche, University of Torino, Turin, Italy.
Department of Medical Science, University of Ferrara, Ferrara, Italy.
Aging Clin Exp Res. 2019 Apr;31(4):557-559. doi: 10.1007/s40520-019-01136-3. Epub 2019 Feb 18.
Recently the Berlin Aging Study II (BASE-II) showed that polypharmacy is associated with clinically relevant sarcopenia among community-dwelling older persons. Here we report findings from the GLISTEN study about the association of polypharmacy with sarcopenia among older medical in-patients.
The GLISTEN study investigated prevalence and clinical correlates of sarcopenia in older patients admitted to geriatric and internal medicine acute care wards of 12 Italian hospitals.
In this sample of older medical in-patients with high prevalence of sarcopenia (34.7%) and polypharmacy (70.2%) we did not observe a significant association of polypharmacy with sarcopenia.
Present findings demonstrate that the association of polypharmacy with sarcopenia, observed in the BASE-II study, is not evident in the GLISTEN sample, being our patients significantly older, more multi-morbid, with high prevalence of sarcopenia and polypharmacy, suggesting that this association might vary according to the heterogeneous health, functional, and nutritional characteristics of older people.
最近的柏林老龄化研究 II 期(BASE-II)表明,社区居住的老年人中,药物使用过多与临床相关的肌肉减少症有关。在此,我们报告了 GLISTEN 研究的结果,该研究探讨了药物使用过多与老年住院患者肌肉减少症之间的关系。
GLISTEN 研究调查了 12 家意大利医院老年科和内科急症病房收治的老年患者中肌肉减少症的患病率和临床相关性。
在本研究中,我们观察到肌肉减少症患病率高(34.7%)和药物使用过多(70.2%)的老年住院患者中,药物使用过多与肌肉减少症之间没有显著关联。
目前的研究结果表明,BASE-II 研究中观察到的药物使用过多与肌肉减少症之间的关联在 GLISTEN 样本中并不明显,因为我们的患者年龄更大、多病共存、肌肉减少症和药物使用过多的患病率更高,这表明这种关联可能因老年人的健康、功能和营养状况的异质性而有所不同。